A randomized, double-blind, placebo-controlled trial of niacinamide for reduction of phosphorus in hemodialysis patients.

Study answer

What this study found

Niacinamide lowered serum phosphorus and the calcium-phosphorus product, and it increased HDL cholesterol when added to binder therapy. In the niacinamide arm, phosphorus decreased from 6.26 +/- 1.28 at week 1 to 5.47 +/- 1.49 at week 9 (P = 0.02), calcium-phosphorus product decreased from 58.72 +/- 12.42 to 51.56 +/- 13.48 (P = 0.02), and HDL increased from 50 +/- 17 to 61 +/- 21 (P = 0.04). The authors concluded it was generally well tolerated and supported further larger randomized trials.

Study & population

Randomized, double-blind, placebo-controlled trial in adults on long-term maintenance hemodialysis with serum phosphorus at least 5.0 mg/dl despite stable phosphorus binder therapy.

Intervention

Niacinamide was given as oral capsules in addition to stable phosphorus binder therapy.

Key limitation

The active arm was small, with only 25 participants analyzed per protocol after 33 were randomized.

View full study detailsView sourceOpen PDF

Original abstract